Header Image for Zyprexa vs KarXT

Zyprexa vs KarXT

Introduction

For patients with schizophrenia or bipolar disorder, medications that modulate neurotransmitter activity in the brain can help stabilize mood swings and manage other symptoms. Zyprexa (olanzapine) and KarXT are two such drugs prescribed for these conditions. Both have antipsychotic effects, but they work through different mechanisms. Zyprexa is classified as an atypical antipsychotic, and primarily affects levels of dopamine and serotonin in the brain to reduce psychotic symptoms and improve mood stability. KarXT is a newer combination medication that contains xanomeline, a muscarinic acetylcholine receptor agonist that targets acetylcholine receptors to alleviate cognitive deficits and the negative symptoms of schizophrenia, along with trospium chloride, an antimuscarinic agent that serves to minimize peripheral side effects. Zyprexa and KarXT leverage distinct pathways to exert effects, but both are used to help patients with psychiatric disorders manage their symptoms and enhance their quality of life.

What is Zyprexa?

Olanzapine (the generic name for Zyprexa) belongs to a class of drugs known as atypical antipsychotics. It was approved by the FDA in 1996. Olanzapine works by modulating neurotransmitters in the brain, specifically acting as an antagonist at dopamine and serotonin receptors. This is thought to underlie its utility in managing symptoms of schizophrenia and bipolar disorder, although the mechanism of action is not entirely understood.

KarXT was also designed to treat psychiatric conditions like schizophrenia, but belongs to an entirely different class of drugs. It is currently under investigation in clinical trials, with promising results from a phase III trial, but it is not yet available for prescription. The FDA is expected to make a decision about the drug's potential approval by September 2024. KarXT represents a novel approach to antipsychotic medications, combining two different drugs–xanomeline and trospium–in fixed doses. Xanomeline acts as an agonist at muscarinic acetylcholine receptors, most notably at M1 and M4 receptors, entering into the central nervous system (CNS) to exhibit effects in the brain. Trospium has antagonistic action at all subtypes of muscarinic acetylcholine receptors but does not cross into the CNS. This combination aims to benefit from the cholinergic activity of xanomeline, while reducing problematic peripheral side effects typical of cholinergic drugs through the addition of trospium.

While both medications are designed to treat similar mental health conditions, their mechanisms differ significantly. Zyprexa influences dopamine and serotonin directly, whereas KarXT targets muscarinic acetylcholine receptors, and also indirectly exerts effects on dopaminergic and glutamatergic pathways involved in schizophrenia and Alzheimer's disease. Due to these differences, the efficacy and side effect profiles of the drugs differ greatly. For instance, Zyprexa is known for its risk of potentially leading to weight gain and metabolic issues such as diabetes, whereas early studies suggest that KarXT may avoid these particular concerns, but could carry a risk of other gastrointestinal side effects or effects related to its cholinergic activity.

What conditions is Zyprexa approved to treat?

Zyprexa (olanzapine) is approved for the treatment of various psychiatric conditions, including:

  • Schizophrenia, in both adults and adolescents
  • Bipolar I disorder (acute manic or mixed episodes), either as monotherapy or in combination with lithium or valproate
  • In maintenance treatment of bipolar disorder to prevent recurrence

How does Zyprexa help with these illnesses?

Zyprexa, known generically as olanzapine, helps to manage symptoms of schizophrenia and bipolar disorder by modulating the activity of certain neurotransmitters in the brain. It primarily works as an antagonist at (partially blocking) dopamine D2 receptors and serotonin 5-HT2A receptors, which are thought to be involved in mood regulation as well as in symptoms of psychosis such as hallucinations or delusions. By balancing levels of these neurotransmitters, Zyprexa can help stabilize mood swings and reduce symptoms of psychosis like agitation, delusions, and paranoia.

What is KarXT?

KarXT is a novel treatment for schizophrenia that combines xanomeline, a muscarinic acetylcholine receptor agonist, with trospium chloride, an antimuscarinic which mitigates the peripheral side effects of xanomeline. This innovative combination selectively targets cholinergic systems in the brain, as opposed to the dopaminergic pathways targeted by other common antipsychotics like Zyprexa (olanzapine). KarXT's unique two-drug formulation works to affect cholinergic pathways in the brain to help manage symptoms of schizophrenia, while avoiding peripheral side effects that commonly occur due to cholinergic drugs. Xanomeline is a muscarinic acetylcholine receptor agonist that targets specific subtypes (primarily M1 and M4) believed to affect cognition and sensory processing, which are affected in conditions including schizophrenia and Alzheimer's disease. Trospium is added to counteract potential peripheral side effects caused by xanomeline's activation of muscarinic receptors outside the central nervous system, thus avoiding some potential impacts on motor function.

KarXT is awaiting regulatory approval after positive results in a phase III clinical trial, and represents an alternative for patients who do not respond well to conventional treatments, or who experience adverse side effects such as sedation and metabolic issues commonly associated with drugs like Zyprexa. By focusing on different neurochemical systems in the body while also reducing unwated side effects, KarXT represents a promising advancement in the management of schizophrenia.

What conditions is KarXT approved to treat?

KarXT is a novel antipsychotic medication that has shown promise in clinical trials for the treatment of:

  • Schizophrenia
  • Psychosis related to Alzheimer's disease

KarXT aims to provide effective symptom relief while reducing the risk of certain problematic side effects associated with some traditional antipsychotic medications, specifically regarding weight gain and metabolic issues.

How does KarXT help with these illnesses?

KarXT represents a novel approach to the management of symptoms of psychosis by selectively targeting muscarinic acetylcholine receptors. Xanomeline is a muscarinic agonist that acts at M1 and M4 muscarinic acetylcholine receptors, which appears to improve negative, positive, and cognitive symptoms of schizophrenia. This is unique compared to the typical and atypical antipsychotics, which largely improve positive symptoms (such as delusions and halluciations) but have questionable effect on negative symptoms (blunted affect, anhedonia, etc.). Further, xanomeline does not block dopamine receptors like the traditional antipsychotics, which not only avoids dopaminergic side effects (such as tardive dyskinesia and parkinsonism) but also represents a new direction in the treatment of schizophrenia.

Unfortunately, cholinergic drugs like xanomeline can have unpleasant side effects such as gastrointestinal upset (nausea, vomiting, diarrhea, etc.) and cardiovascular disturbances. The addition of trospium is meant to limit these peripheral side effects, meaning outside the central nervous system, because trospium is an antimuscarinic, working counter to the action of xanomeline. However, trospium does not cross into the central nervous system and brain, so xanomeline is left to exert its effect in the CNS while being counteracted by trospium at peripheral sites. This combination is unique and has shown promise in alleviating symptoms of psychosis while avoiding side effects common to dopaminergic antipsychotics and to typical muscarinic agonists.

Since it operates through a distinct mechanism, KarXT represents an alternative option for patients who may not respond well to conventional treatments, or who experience significant unpleasant adverse effects from other drugs.

How effective are Zyprexa and KarXT?

Both Zyprexa (olanzapine) and KarXT (xanomeline-trospium) have demonstrated efficacy in treating patients with schizophrenia, though they belong to entirely different classes of medications and act on distinct neurotransmitter systems. Olanzapine is an atypical antipsychotic approved by the FDA in 1996, which primarily targets dopamine D2 receptors and serotonin 5-HT2A receptors. In contrast, KarXT is a novel combination therapy that includes xanomeline, a muscarinic acetylcholine receptor agonist that targets M1/M4 receptors for antipsychotic effects, along with trospium, an antimuscarinic, to prevent unwanted peripheral side effects.

Both drugs have shown promising results in managing symptoms of schizophrenia in clinical trials, although olanzapine has been around for nearly 30 years and KarXT is a novel drug just emerging from investigational studies. Studies have demonstrated that olanzapine is effective at reducing both positive and negative symptoms of schizophrenia, and has a favorable safety profile. It is known for its rapid onset of action, but it also carries a risk of undesirable side effects such as weight gain and metabolic syndrome. Phase II and III clinical trials for KarXT indicated significant improvements in symptomatology of schizophrenia compared to placebo, and the drug did not induce common side effects associated with traditional antipsychotics like weight gain or metabolic disturbances. KarXT leverages distinct phsyiological mechanisms and thus represents a potentially beneficial alternative for patients who may not tolerate standard treatments due to their side effect profiles. However, being relatively new means there are fewer longitudinal studies confirming the long-term benefits and potential adverse outcomes associated with KarXT.

Ultimately, choosing between these two medications will depend significantly on individual patient factors, including particulars and severity of the diagnosis, response to prior treatments, tolerability, and personal preferences/needs.

At what dose is Zyprexa typically prescribed?

Oral dosages of Zyprexa (olanzapine) typically range from 5–20 mg/day for treating schizophrenia and bipolar disorder, with many patients finding effective symptom control at around 10 mg/day. The dosage can be adjusted under the guidance of a physician or pscyhiatrist based on individual response and tolerability, but should not exceed the maximum recommended dose of 20 mg/day. Always follow your healthcare provider's recommendations for dosage adjustments, and do not exceed the dosage you've been prescribed to minimize potential side effects or adverse reactions.

Find Top Clinical Trials

Choose from over 30,000 active clinical trials.

At what dose is KarXT typically prescribed?

KarXT treatment is awaiting FDA approval, at which point the dosage of the drug will be formalized. In clinical trials, patients were given mixtures of either 50 mg xanomeline and 20 mg trospium, or 100 mg xanomeline and 20 mg trospium. In the final formulation, the proportions of the two active ingredients will be standardized, and the dosage recommendations will be clarified.

What are the most common side effects of Zyprexa?

Common side effects of Zyprexa include:

  • Somnolence (sleepiness/drowsiness)
  • Weight gain
  • Increased appetite
  • Orthostatic hypotension (a form of low blood pressure that happens when standing up from sitting or lying down)
  • Dry mouth
  • Dizziness, asthenia (general weakness and fatigue), and/or tremors (unintentional trembling or shaking)
  • Constipation and dyspepsia (burning discomfort in the digestive tract)

You should closely monitor your health while taking Zyprexa, and speak to your healthcare provider if you experience any of the above symptoms or other changes to your health.

Are there any potential serious side effects for Zyprexa?

Zyprexa also carries a risk of more serious side effects. Please seek medical assistance urgently if you experience any of the following:

  • Increased thoughts about suicide or self-harm
  • Signs of allergic reactions such as hives, difficulty breathing, swelling in your face or throat, fever, sore throat, burning eyes, skin pain, or a red or purple skin rash with blistering and peeling.
  • Eye problems, such as: blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights
  • Fast or pounding heartbeat, or a fluttering in your chest
  • hortness of breath and sudden dizziness (feeling like you might pass out)
  • Symptoms of low sodium levels, such as: headache, confusion, slurred speech, severe weakness, vomiting, loss of coordination, feeling unsteady.
  • Signs of a severe nervous system reaction characterized by very stiff (rigid) muscles, high fever, sweating, confusion, a fast or uneven heartbeat, and tremors or feeling faint

If you experience any of these symptoms, please consult with a healthcare professional immediately to avoid potentially serious complications.

What are the most common side effects of KarXT?

In clinical trials, KarXT was shown to exhibit side effects including:

  • Dry mouth
  • Nausea
  • Constipation
  • Headache
  • Dyspepsia (indigestion)
  • Hypertension (high blood pressure)
  • Dizziness
  • GERD (gastro-oesophageal reflux disease)

KarXT appears to be less likely than Zyprexa to cause significant weight gain or severe metabolic issues due to its different mechanism of action. Patients using KarXT might also experience fewer sedative effects compared to those on Zyprexa. Always speak with your healthcare provider when considering KarXT and closely monitor your health to watch for potential side effects such as those listed above.

Are there any potential serious side effects for KarXT?

There are some potentially serious side effects of KarXT that might require immediate medical attention. Please seek urgent medical assistance if you experience any of the following:

  • Signs of allergic reactions or severe skin reactions such as: hives, itching, fever, swollen glands, difficulty breathing, swelling in your face or throat, sore throat, burning eyes, skin pain with red or purple rash that blisters and peels
  • Increased suicidal thoughts or thoughts about self-harm
  • Experiencing a seizure (convulsions)
  • Confusion and unusual changes in mood or behavior
  • Blurred vision including tunnel vision or seeing halos around lights
  • Eye pain or swelling
  • A fast or irregular heartbeat
  • Signs of a manic episode, which include: racing thoughts, increased energy levels leading to reckless behavior, and extreme happiness or irritability.

If you encounter any of these symptoms while taking KarXT, it’s crucial to seek medical attention immediately.

Contraindications for Zyprexa and KarXT

Both Zyprexa and KarXT, like many other antipsychotic medications, can have significant side effects and may not be suitable for everyone. If you experience worsening symptoms or severe side effects such as increased agitation, confusion, or suicidal thoughts, or signs of an allergic reaction while taking either medication, seek immediate medical attention.

Neither Zyprexa nor KarXT should be taken if you are currently using monoamine oxidase inhibitors (MAOIs) or have recently discontinued them. It is crucial to inform your physician about all the medications you are taking. MAOIs typically require a washout period of about 2 weeks to clear from the system before starting new treatments with antipsychotics like Zyprexa or KarXT in order to prevent dangerous drug interactions.

Both drugs are prescription-only, and should be used exactly as directed.

How much do Zyprexa and KarXT cost?

For the brand name versions of these drugs:

  • The price of 30 tablets of Zyprexa (10 mg) averages around $1,000, which works out to about $33/day.
  • The price for a month's supply (60 capsules) of KarXT is roughly $3,500 to $5,000 depending on the pharmacy and your location. This translates to approximately $116–$166 per day.

Thus, Zyprexa may be less expensive on a per-day treatment basis compared to KarXT. However, these drugs work through entirely different mechanisms of action and cost should not be the primary consideration in determining which medication is appropriate for you. That choice will be made together with your doctor based on individual patient characteristics and preferences.

Currently, there are no generic alternatives available for KarXT as it is still under patent protection. On the other hand, generic olanzapine (the active ingredient in Zyprexa) costs significantly less than Zyprexa. Prices typically range from $0.50 to $2 per 10 mg tablet, depending on dose strength and quantity purchased. That can work out to anywhere from just $0.50 up to $4.00 per day of treatment.

Patients should discuss clinical benefits, side effects, and financial implications with their healthcare provider when selecting medications for schizophrenia and other mental health disorders.

Popularity of Zyprexa and KarXT

Zyprexa, known generically as olanzapine, was prescribed to approximately 2.7 million people in the US in 2020. Olanzapine is a widely used antipsychotic medication that accounts for about 15% of prescriptions within its class. It has been utilized extensively since its approval in the mid-1990s, and remains a staple treatment for conditions such as schizophrenia and bipolar disorder.

In contrast, KarXT (a combination of xanomeline and trospium) represents a newer class of medications aimed at treating psychiatric disorders with fewer side effects related to weight gain or metabolic issues compared to traditional antipsychotics like olanzapine. Although precise prescription data for KarXT is not yet available due to its recent introduction, it shows promise based on clinical trials which highlighted its efficacy in managing symptoms of schizophrenia and its improved safety profile.

While olanzapine continues to be prevalent due to established trust among healthcare providers and patients alike, emerging treatments like KarXT offer hope for better tolerability without compromising on therapeutic benefits.

Conclusion

Both Zyprexa (olanzapine) and KarXT (xanomeline-trospium) are used in the treatment of schizophrenia, but they have distinct mechanisms of action and clinical profiles. Zyprexa is a well-established atypical antipsychotic that primarily works by antagonizing dopamine D2 receptors and serotonin 5-HT2A receptors, which helps to mitigate both the positive and negative symptoms of schizophrenia. Zyprexa has been available since the late 1990s, and is often prescribed as a first-line therapy due to extensive evidence of its efficacy. However, it is associated with potential metabolic side effects such as weight gain, increased risk of diabetes, and dyslipidemia.

KarXT represents a novel approach to antipsychotic medications, combining the muscarinic receptor agonist xanomeline with the peripherally restricted antimuscarinic trospium chloride to reduce peripheral side effects while selectively targeting cholinergic pathways in the central nervous system involved in psychosis. This unique mechanism offers potential benefits for patients who may not respond adequately or tolerate traditional antipsychotics like Zyprexa. Being relatively new, long-term data on safety and efficacy is still emerging.

Patients should discuss their options for antipsychotic medications carefully with their healthcare provider, considering factors like clinical benefit, tolerability and side effect profiles, and individual needs and preferences. All antipsychotic treatment regimens require guidance by a healthcare professional to watch for potential side effects and ensure patient safety. Patients should seek emergency medical assistance if they experience any sudden or worrying changes to their health.

Refrences

  • Dean, B., & Scarr, E. (2020, June). Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia. Psychiatry Research. Elsevier BV.http://doi.org/10.1016/j.psychres.2020.112989
  • Araszkiewicz, A. A., Szabert, K., Godman, B., Wladysiuk, M., Barbui, C., & Haycox, A. (2008, December). Generic olanzapine: health authority opportunity or nightmare?. Expert Review of Pharmacoeconomics & Outcomes Research. Informa UK Limited.http://doi.org/10.1586/14737167.8.6.549
  • Wagstaff, A. J., Easton, J., & Scott, L. J. (2005). Intramuscular Olanzapine. CNS Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00023210-200519020-00005
  • Lieberman, D. Z., & Goodwin, F. K. (2004, September). Use of olanzapine in the treatment of bipolar I disorder. Expert Review of Neurotherapeutics. Informa UK Limited.http://doi.org/10.1586/14737175.4.5.759
  • McCormack, P. L., & Wiseman, L. R. (2004). Olanzapine. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00003495-200464230-00006
  • Shekhar, A., M.D., Ph.D, Potter, W. Z., M.D., Ph.D, Lightfoot, J., Ph.D., Lienemann, J., D.Pharm., Dubé, S., M.D., Mallinckrodt, C., Ph.D., … Felder, C. C., Ph.D. (2008, August). Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia. American Journal of Psychiatry. American Psychiatric Association Publishing.http://doi.org/10.1176/appi.ajp.2008.06091591
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top